Esperion Therapeutics shares are trading lower after B of A Securities downgraded the stock from Neutral to Underperform.
Portfolio Pulse from Benzinga Newsdesk
Esperion Therapeutics shares are trading lower after B of A Securities downgraded the stock from Neutral to Underperform.
June 20, 2024 | 2:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Esperion Therapeutics shares are trading lower following a downgrade by B of A Securities from Neutral to Underperform.
The downgrade by a major financial institution like B of A Securities is likely to negatively impact investor sentiment and lead to a short-term decline in the stock price of Esperion Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100